Recruiting at 1 site Phase 4 Critical Limb Ischemia

Critical Limb Ischemia study: Stempeucel®

Official title Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease

ClinicalTrials.gov ID: NCT05854641

What this study is testing

What is Stempeucel®?

This is an investigational treatment being studied for critical limb ischemia. It is designed to be injected into the muscle to help improve blood flow and healing in the legs.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study wants to see if Stempeucel® injections can lessen pain and improve healing in these patients and whether it causes serious side‑effects.
Who it's for
Adults in Malaysia who have critical limb ischemia caused by peripheral arterial disease.
What's involved
Participants receive Stempeucel® injections into the leg muscle and are monitored by the study doctor. They will have follow‑up visits for safety and effectiveness checks.
Time commitment
The study lasts up to one year after the injection, with regular follow‑up visits during that time.
  • Phase 4: studies an already-approved treatment

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 65

You may be able to join if

  • Patients between 18-65 years old
  • Patients diagnosed with atherosclerotic peripheral arterial disease
  • Patients not eligible for or have failed surgical or percutaneous revascularization (No option patients)
  • Patients with at least one ulcer (between 0.5 to 10 cm2 size)
  • Ankle brachial pressure index (ABPI) ≤ 0.6 (toe brachial index (TBI) if ABPI out of range; TBI ≤ 0.5)

You likely can't join if

  • Patients diagnosed with Buerger's disease by Shionoya criteria
  • Patients eligible for surgical or percutaneous revascularization
  • Patients with a history of participating in another stem cell trial or therapy within 3 months
  • Patients who are unsuitable to participate the clinical trial as determined by investigators
See the full eligibility criteria
Who can join
  • Patients between 18-65 years old
  • Patients diagnosed with atherosclerotic peripheral arterial disease
  • Patients not eligible for or have failed surgical or percutaneous revascularization (No option patients)
  • Patients with at least one ulcer (between 0.5 to 10 cm2 size)
  • Ankle brachial pressure index (ABPI) ≤ 0.6 (toe brachial index (TBI) if ABPI out of range; TBI ≤ 0.5)
  • Patients who are able and willing to provide consent and agrees to comply with study procedures and follow-up evaluations
What rules you out
  • Patients diagnosed with Buerger's disease by Shionoya criteria
  • Patients eligible for surgical or percutaneous revascularization
  • Patients with a history of participating in another stem cell trial or therapy within 3 months
  • Patients who are unsuitable to participate the clinical trial as determined by investigators

The study team makes the final eligibility decision.

Where it is enrolling

  • Kuala Lumpur, Malaysia

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Kuala Lumpur, Malaysia. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.